Oncolytics Biotech (TSE:ONC) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Oncolytics Biotech, an immunotherapy specialist in the oncology field, announced their participation in Canaccord Genuity’s 44th Annual Growth Conference, featuring a fireside chat with CMO Dr. Thomas Heineman. The biotech company, known for developing pelareorep, an immune-therapeutic agent showing promise in cancer treatment, will also engage in one-on-one investor meetings during the event. The conference will provide an opportunity to gain insights into Oncolytics’ progress on pelareorep, which has been granted Fast Track designation by the FDA for its potential in treating metastatic breast and pancreatic cancers.
For further insights into TSE:ONC stock, check out TipRanks’ Stock Analysis page.